Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype.

Matteo TomaGiulio SavonittoCarlo Maria LombardiEdoardo AiròMauro DriussiPiero GentileLuke HowardMartina MoschellaEmma Di PoiMatteo PagnesiSimonetta MontiValentino ColliniLuciana D'AngeloVeronica VecchiatoAlberto GiannoniMarianna AdamoDavide BarbisanCarolina BauleoAndrea GarasciaMarco MetraGianfranco SinagraFrancesco Lo GiudiceDavide StolfoPietro Ameri

Published in: Clinical research in cardiology : official journal of the German Cardiac Society (2024)

In real life, PAH-LHD patients are frequent, have less severe disease and are less likely treated with PAH drug combinations than no-LHD. The COMPERA 2.0 model may be more appropriate to evaluate their mortality risk during follow-up and how it is modulated by therapy.

Keyphrases

pulmonary arterial hypertension
risk assessment
pulmonary hypertension
end stage renal disease
newly diagnosed
pulmonary artery
chronic kidney disease
ejection fraction
prognostic factors
emergency department
early onset
heavy metals
stem cells
human health
adverse drug
cell therapy
smoking cessation